(Melphalan) Tablets 2 mg (Melphalan) for Injection 50 mg
Alkeran® tablets are indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary. Alkeran for Injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
ALKERAN (melphalan) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Severe bone marrow suppression with resulting infection or bleeding may occur. Melphalan is leukemogenic in humans.
Melphalan produces chromosomal aberrations in vitro and in vivo and, therefore, should be considered potentially mutagenic in humans.